Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicenter Randomized Trial to Assess the Efficacy and Safety of First Line Nivolumab in Combination With Paclitaxel in Subjects With R/M HNSCC Unable for Cisplatin-based Chemotherapy (NIVOTAX)

NCT04282109 is registered in ClinicalTrials.gov with Grupo Español de Tratamiento de Tumores de Cabeza y Cuello as lead sponsor.

NCT NCT04282109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04282109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicenter Randomized Trial to Assess the Efficacy and Safety of First Line Nivolumab in Combination With Paclitaxel in Subjects With R/M HNSCC Unable for Cisplatin-based Chemotherapy (NIVOTAX)
Lead sponsor
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase
Phase 2
Overall status
Completed
Start date
June 3, 2020
Completion date
March 21, 2024
Enrollment
141 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent/metastatic head and neck squamous cell carcinoma